These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8915301)
21. Time-course of iodine elimination by hemodialysis in patients with renal failure after angiography. Shinoda T; Hata T; Nakajima K; Yoshimoto H; Niwa A Ther Apher; 2002 Dec; 6(6):437-42. PubMed ID: 12460407 [TBL] [Abstract][Full Text] [Related]
22. Effect of hemodialysis on ceftazidime pharmacokinetics. Nikolaidis P; Tourkantonis A Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438 [TBL] [Abstract][Full Text] [Related]
23. [Effects of intravenous injection of ioversol, a nonionic contrast medium, on circulating blood volume: comparison among different combinations of its dose and volume injected]. Sakuma I; Sakuma K; Fukao M; Akaishi Y; Asajima H; Sato M; Shudo H; Numazawa K; Kakinoki S; Kitabatake A Kokyu To Junkan; 1993 Dec; 41(12):1191-5. PubMed ID: 8284543 [TBL] [Abstract][Full Text] [Related]
24. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis. Gheuens E; Daelemans R; Mesens S Invest Radiol; 2014 Aug; 49(8):505-8. PubMed ID: 24619209 [TBL] [Abstract][Full Text] [Related]
25. A randomized double-blind trial of ioversol and iopamidol in contrast-enhanced computed body tomography. Sage MR; Evill CA; Fon GT Invest Radiol; 1989 Jun; 24 Suppl 1():S39-41. PubMed ID: 2687194 [TBL] [Abstract][Full Text] [Related]
26. Ioversol 320: a new nonionic, water-soluble contrast medium for body computed tomography clinical trial. Kopecky KK; Becker GJ; Conces DJ Invest Radiol; 1989 Jun; 24 Suppl 1():S33-4. PubMed ID: 2687192 [TBL] [Abstract][Full Text] [Related]
27. [Ioversol 350: clinical experience in skull x-ray computed tomography]. Théron J; Paugam JP; Courthéoux P Ann Radiol (Paris); 1991; 34(6-7):413-7. PubMed ID: 1822666 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836 [TBL] [Abstract][Full Text] [Related]
29. The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Jost G; Pietsch H; Lengsfeld P; Hütter J; Sieber MA Invest Radiol; 2010 May; 45(5):255-61. PubMed ID: 20375847 [TBL] [Abstract][Full Text] [Related]
30. The effect of hemodialysis on piperacillin pharmacokinetics. Heim-Duthoy KL; Halstenson CE; Abraham PA; Matzke GR Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):680-4. PubMed ID: 3818147 [TBL] [Abstract][Full Text] [Related]
31. Elimination characteristics of bredinin from patients serum in hemodialysis. Takada K; Yoshikawa H; Muranishi S; Takahara S; Nagano S; Fukunishi T; Sonoda T; Ichikawa Y Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):197-9. PubMed ID: 3997305 [TBL] [Abstract][Full Text] [Related]
32. Clearance of theophylline by hemodialysis in one patient with chronic renal failure. Chang DB; Kuo SH; Yang PC; Shen FH; Luh KT Chest; 1992 Nov; 102(5):1621-3. PubMed ID: 1424911 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583 [TBL] [Abstract][Full Text] [Related]
34. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261 [TBL] [Abstract][Full Text] [Related]
35. [Usefulness of ioversol (MP-328) in angiocardiography--a multicenter comparative study with iopamidol]. Morimoto S; Kozuka T; Takamiya M; Kimura K; Matsuyama S; Kuribayashi S; Shigeta A; Umemura J; Harada J; Yamada T Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Sep; 50(9):1087-101. PubMed ID: 2247350 [TBL] [Abstract][Full Text] [Related]
36. Contrast enhancement in electron beam tomography of the heart: comparison of a monomeric and a dimeric iodinated contrast agent in 59 patients. Enzweiler CN; Höhn S; Taupitz M; Lembcke AE; Wiese TH; Hamm B; Kivelitz DE Acad Radiol; 2006 Jan; 13(1):95-103. PubMed ID: 16399037 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of iopentol in the rat. Michelet AA; Skinnemoen K Acta Radiol Suppl; 1987; 370():101-4. PubMed ID: 2980301 [TBL] [Abstract][Full Text] [Related]
39. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Moon SS; Bäck SE; Kurkus J; Nilsson-Ehle P Nephron; 1995; 70(4):430-7. PubMed ID: 7477648 [TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. Pioger JC; Taburet AM; Colin JN; Colaneri S; Fillastre JP; Singlas E Therapie; 1989; 44(6):401-4. PubMed ID: 2623653 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]